{"id":44711,"date":"2021-06-01T08:01:50","date_gmt":"2021-06-01T12:01:50","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=44711"},"modified":"2021-06-01T00:37:13","modified_gmt":"2021-06-01T04:37:13","slug":"merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711","title":{"rendered":"Merck &#038; Co., Inc (NYSE: MRK) Gains A Upper Hand Against Pfizer Inc (NYSE: PFE) In Timing Of next-gen Pneumococcal Vaccines For Kids"},"content":{"rendered":"<p><b>Pfizer Inc (NYSE: PFE) <\/b><span style=\"font-weight: 400;\">and <\/span><b>Merck &amp; Co., Inc (NYSE: MRK) <\/b><span style=\"font-weight: 400;\">are in race to expedite the launch of next-gen pneumococcal\u00a0vaccines by the end of this year. However, Merck gains an upper hand for kids\u2019 vaccines.<\/span><\/p>\n<p><b>Timing advantage<\/b><\/p>\n<p><span style=\"font-weight: 400;\">In a communiqu\u00e9, Merck said its V114 completed the efficacy and safety thresholds in two phase 3 clinical trials and gains an advantage over Pfizer in the timing of the launch. As a result, Merck could submit for kids\u2019 vaccines by the end of this year. On the other hand, Pfizer expects its readout of pneumococcal candidate\u2019s late pediatric data in 2022.\u00a0<\/span><\/p>\n<p><b>FDA to promulgate its decisions soon<\/b><\/p>\n<p><span style=\"font-weight: 400;\">However, both Pfizer and Merck are in the race in adult vaccines by completing the FDA reviews. Merck expects a reply from FDA in July 2021 for its 15-valent candidate whereas Pfizer will receive the decision of the regulator in June 2021 for its 20-valent shot.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Merck said its drug V114 achieved its primary immunogenicity\u00a0and safety endpoints in an interchangeability study conducted in healthy infants aged between 42 and 90 days.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">As part of the Pneu-Plan catch-up\u00a0clinical trial, investigators\u00a0conducted tests in healthy kids aged between seven months and 17 years using V114. Those kids and adolescents have not previously received pneumococcal vaccines. Both Prevnar 13 and V114 demonstrated similar immune responses in the clinical trial. Merck will share the clinical trial outcome at the forthcoming medical congress.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Merck said the trial outcomes help it to tell the parents of infants to switch to its 13-valent vaccine. It could also suggest this vaccine for children, who have not previously been given a pneumococcal shot.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Pfizer amassed significant revenues for several years by offering its Prevnar 13, a pneumococcal stalwart and the best-selling vaccine worldwide. However, it will add significant revenues from COVID-19 vaccines from this year changing the history.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Merck is in the race for almost 10 years using its\u00a0pneumococcal conjugate vaccine after posting success in 2011 with its first formulation. However, it is not optimal for kids. Therefore, Merck halted the program and incorporated several changes over several years to unveil a high-quality product in the market.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Cantor Fitzgerald analysts\u00a0in February 2021 said Pfizer&#8217;s 20-valent candidate could be a better option compared to Merck\u2019s 15-valet shot. They also said Merck has an advantage in V114 in serotype 3. The team said Merck could significantly increase its revenues because of blockbuster opportunities in the lucrative pneumococcal field.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc (NYSE: PFE) and Merck &amp; Co., Inc (NYSE: MRK) are in race to expedite the launch of next-gen pneumococcal\u00a0vaccines by the end of [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":43994,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1684,15502,1123,3275,15501],"stock_ticker":[13841],"class_list":["post-44711","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-merck-co-inc-nyse-mrk","tag-nyse-pfe","tag-nysemrk","tag-pfizer-inc","tag-pfizer-inc-nyse-pfe","stock_ticker-pfe","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck &amp; Co., Inc (NYSE: MRK) Gains A Upper Hand Against Pfizer Inc (NYSE: PFE) In Timing Of next-gen Pneumococcal Vaccines For Kids - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck &amp; Co., Inc (NYSE: MRK) Gains A Upper Hand Against Pfizer Inc (NYSE: PFE) In Timing Of next-gen Pneumococcal Vaccines For Kids - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc (NYSE: PFE) and Merck &amp; Co., Inc (NYSE: MRK) are in race to expedite the launch of next-gen pneumococcal\u00a0vaccines by the end of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-01T12:01:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2021\/01\/Pfizer-vaccines.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"Merck &#038; Co., Inc (NYSE: MRK) Gains A Upper Hand Against Pfizer Inc (NYSE: PFE) In Timing Of next-gen Pneumococcal Vaccines For Kids\",\"datePublished\":\"2021-06-01T12:01:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711\"},\"wordCount\":419,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2021\/01\/Pfizer-vaccines.jpg\",\"keywords\":[\"Merck &amp; Co Inc. (NYSE: MRK)\",\"NYSE: PFE\",\"NYSE:MRK\",\"Pfizer Inc.\",\"Pfizer Inc. (NYSE: PFE)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711\",\"name\":\"Merck & Co., Inc (NYSE: MRK) Gains A Upper Hand Against Pfizer Inc (NYSE: PFE) In Timing Of next-gen Pneumococcal Vaccines For Kids - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2021\/01\/Pfizer-vaccines.jpg\",\"datePublished\":\"2021-06-01T12:01:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2021\/01\/Pfizer-vaccines.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2021\/01\/Pfizer-vaccines.jpg\",\"width\":750,\"height\":500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck &#038; Co., Inc (NYSE: MRK) Gains A Upper Hand Against Pfizer Inc (NYSE: PFE) In Timing Of next-gen Pneumococcal Vaccines For Kids\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck & Co., Inc (NYSE: MRK) Gains A Upper Hand Against Pfizer Inc (NYSE: PFE) In Timing Of next-gen Pneumococcal Vaccines For Kids - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711","og_locale":"en_US","og_type":"article","og_title":"Merck & Co., Inc (NYSE: MRK) Gains A Upper Hand Against Pfizer Inc (NYSE: PFE) In Timing Of next-gen Pneumococcal Vaccines For Kids - Wall Street PR","og_description":"Pfizer Inc (NYSE: PFE) and Merck &amp; Co., Inc (NYSE: MRK) are in race to expedite the launch of next-gen pneumococcal\u00a0vaccines by the end of [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2021-06-01T12:01:50+00:00","og_image":[{"width":750,"height":500,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2021\/01\/Pfizer-vaccines.jpg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"Merck &#038; Co., Inc (NYSE: MRK) Gains A Upper Hand Against Pfizer Inc (NYSE: PFE) In Timing Of next-gen Pneumococcal Vaccines For Kids","datePublished":"2021-06-01T12:01:50+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711"},"wordCount":419,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2021\/01\/Pfizer-vaccines.jpg","keywords":["Merck &amp; Co Inc. (NYSE: MRK)","NYSE: PFE","NYSE:MRK","Pfizer Inc.","Pfizer Inc. (NYSE: PFE)"],"articleSection":["Health"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711","url":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711","name":"Merck & Co., Inc (NYSE: MRK) Gains A Upper Hand Against Pfizer Inc (NYSE: PFE) In Timing Of next-gen Pneumococcal Vaccines For Kids - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2021\/01\/Pfizer-vaccines.jpg","datePublished":"2021-06-01T12:01:50+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2021\/01\/Pfizer-vaccines.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2021\/01\/Pfizer-vaccines.jpg","width":750,"height":500},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-co-inc-nyse-mrk-gains-a-upper-hand-against-pfizer-inc-nyse-pfe-in-timing-of-next-gen-pneumococcal-vaccines-for-kids-44711#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Merck &#038; Co., Inc (NYSE: MRK) Gains A Upper Hand Against Pfizer Inc (NYSE: PFE) In Timing Of next-gen Pneumococcal Vaccines For Kids"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/44711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=44711"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/44711\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/43994"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=44711"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=44711"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=44711"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=44711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}